

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/940,925	08/28/2001	James E. Dahlberg	FORS-06612	6817
23535 75	590 03/31/2004		EXAM	INER
MEDLEN & CARROLL, LLP			SULLIVAN, DANIEL M	
101 HOWARD SUITE 350	STREET		ART UNIT	PAPER NUMBER
	SCO, CA 94105		1636	
			DATE MAIL ED. 02/21/200	4

DATE MAILED: 03/31/2004

Please find below and/or attached an Office communication concerning this application or proceeding.



## **Advisory Action**

	Application No.	Applicant(s)	
09/940,925		DAHLBERG ET AL.	
	Examiner	Art Unit	
	Daniel M Sullivan	1636	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 19 March 2004 FAILS TO PLACE THIS APPLICATION Therefore, further action by the applicant is required to avoid abandonment of final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendon for allowance; (2) a timely filed Notice of Appeal (with appeal fee); of Examination (RCE) in compliance with 37 CFR 1.114.	of this application. A proper reply to a ndment which places the application in
PERIOD FOR REPLY [check either a	a) or b)]
a) The period for reply expiresmonths from the mailing date of the final rejection	
b) Make the period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the no event, however, will the statutory period for reply expire later than SIX MONTHS ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO M 706.07(f).	from the mailing date of the final rejection.
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition fee have been filed is the date for purposes of determining the period of extension and the corresponder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory processes (2) as set forth in (b) above, if checked. Any reply received by the Office later than three month timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).	esponding amount of the fee. The appropriate extension period for reply originally set in the final Office action; or
1. A Notice of Appeal was filed on Appellant's Brief must be filed 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid	·
2. The proposed amendment(s) will not be entered because:	
(a) X they raise new issues that would require further consideration and	l/or search (see NOTE below);
(b) they raise the issue of new matter (see Note below);	
(c) they are not deemed to place the application in better form for application issues for appeal; and/or	peal by materially reducing or simplifying the
(d) they present additional claims without canceling a corresponding	number of finally rejected claims.
NOTE: See Continuation Sheet.	
3. Applicant's reply has overcome the following rejection(s):	
4. Newly proposed or amended claim(s) would be allowable if submodule canceling the non-allowable claim(s).	mitted in a separate, timely filed amendment
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has application in condition for allowance because: <u>See Continuation Sheet</u> .	
6. The affidavit or exhibit will NOT be considered because it is not directe raised by the Examiner in the final rejection.	ed SOLELY to issues which were newly
7. For purposes of Appeal, the proposed amendment(s) a) will not be explanation of how the new or amended claims would be rejected is p	,
The status of the claim(s) is (or will be) as follows:	
Claim(s) allowed:	
Claim(s) objected to:	
Claim(s) rejected: <u>71-94</u> .	
Claim(s) withdrawn from consideration:	
8.⊠ The drawing correction filed on 19 March 2004 is a)⊠ approved or b)	disapproved by the Examiner.
9. Note the attached Information Disclosure Statement(s)( PTO-1449) Pa	•
10. ☑ Other: See Continuation Sheet	

PHIWARY EXAMINER

Continuation of 2. NOTE: According to the proposed amendment, the method of claim 71 and claims depending therefrom would now be limited to comprising an enzyme comprising a 5' nuclease. Although pending claim 85 is directed to the method wherein the "cleavage means" is an enzyme comprising a 5' nuclease, it is not clear that the scope of this claim is the same as the scope of claim 71 as amended in the present claim set because the 5' nuclease is no longer limited to being a "cleavage means". The term "cleavage means" is defined in the paragraph bridging pages 33-34 of the specification and relates to "any means which is capable of cleaving a cleavage structure..." The term "cleavage structure" is defined in the paragraph immediately preceding the definition of "cleavage means" and relates to "a region of a single-stranded nucleic acid substrate containing secondary structure..." As the 5' nuclease of the proposed amendment is no longer limited to being a "cleavage means", it would seem that the scope of the 5' nuclease is expanded to encompass nucleases that are incapable of cleaving a "cleavage structure". This difference in scope raises new issues requiring additional search and examination.

Continuation of 5. does NOT place the application in condition for allowance because: Applicant's arguments regarding the outstanding rejections are predicated on entry of the amendment. As the amendment has not been entered, these arguments are moot.

Continuation of 10. Other: It is noted that the Brief Description of the Drawings does not contain a description of Figure 1C. Applicant is urged to review the Brief Description section and provide a description of each drawing, being careful not to introduce new matter.